← Eichor
Condition: Sublingual Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Sublingual

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Management of Moderate to Severe Monotraumatic Pain With Sublingual Sufentanil in an Emergency Situation.
Phase 3 · 1 location(s) · University Hospital, Clermont-Ferrand · NCT06917651
Prevention With Ismigen of RTIs in Kids
Phase 4 · 10 location(s) · Lallemand Pharma AG · NCT07578012
Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases
NA · 1 location(s) · University Hospital, Lille · NCT04119908
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
Phase 1 · 1 location(s) · Intra-Cellular Therapies, Inc. · NCT06299410
Sublingual Caffeine on Reducing Recovery Time and Postoperative Agitation in Elderly Patients Undergoing General Anesthe
NA · 1 location(s) · Cairo University · NCT07536568
Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma
Phase N/A · 1 location(s) · Fondation Ophtalmologique Adolphe de Rothschild · NCT05264818
Effects of Intravenous Metabolic Recovery Agent in Elderly Septic Patients on Prognosis and Microcirculation.
NA · 1 location(s) · Southeast University, China · NCT06723626
Buprenorphine for Individuals in Jail
Phase 3 · 2 location(s) · Friends Research Institute, Inc. · NCT06306443
Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Is
Phase 4 · 1 location(s) · Ruijun Ji · NCT07119021
Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project
NA · 1 location(s) · Fundación de Investigación Biomédica - Hospital Universitari · NCT07419230
Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
Phase 3 · 1 location(s) · Peking Union Medical College Hospital · NCT06674460
SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
Phase N/A · 12 location(s) · Bial - Portela C S.A. · NCT07145190
The Use of Sublingual Melatonin Premedication in Geriatric Cataract Surgery
Phase 4 · 2 location(s) · Al-Azhar University · NCT07036367
Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)
Phase 2 · 9 location(s) · University of North Carolina, Chapel Hill · NCT06636786
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Phase 1 · 1 location(s) · Pharmacotherapies for Alcohol and Substance Use Disorders Al · NCT06335407
Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients
Phase 2 · 21 location(s) · Simcere Pharmaceutical Co., Ltd · NCT06315231
Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study
Phase 4 · 1 location(s) · Chuansheng Zhao · NCT07454473
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
Phase 3 · 19 location(s) · Inmunotek S.L. · NCT07348302
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
Phase 1/Phase 2 · 1 location(s) · Biolingus · NCT05268237
BXCL501 After Stress to Increase Recovery Success
Phase 2 · 3 location(s) · University of North Carolina, Chapel Hill · NCT06943404
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.